Evidence map›Paper›PMID 37867613›Full record

ArticleClinical and translational radiation oncology2023

Efficacy and safety analysis in metastatic cancer patients treated with multiple courses of repeat radiation therapy.

Maiwand Ahmadsei, Sebastian M Christ, Tiuri E Kroese, Anja Kühnis, Jonas Willmann, Panagiotis Balermpas, Nicolaus Andratschke, Stephanie Tanadini-Lang, Matthias Guckenberger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maiwand AhmadseiDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Sebastian M ChristDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Tiuri E KroeseDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Anja KühnisDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Jonas WillmannDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Panagiotis BalermpasDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Nicolaus AndratschkeDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Stephanie Tanadini-LangDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology and Competence Center for Palliative Care, University Hospital and University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Due to advances in oncology, a growing proportion of patients is treated with repetitive courses of radiotherapy. The aim of this study is to analyze whether radiotherapy maintains its safety and efficacy profile in patients treated with multiple repeat courses of irradiation. Material and methods: All patients treated between 2011 and 2019 at our institution were screened for a minimum of five repeat irradiation courses, to analyze treatment characteristics, survival, safety and efficacy. The type of re-irradiation was classified according to ESTRO-EORTC consensus guidelines. Results: A total of n = 112 patients receiving n = 660 radiotherapy courses were included in this retrospective cohort study. The most frequent primary tumors were lung cancer in 41.9 % (n = 47) and malignant melanoma in 8.9 % (n = 10). The most frequent re-irradiation types were repeat irradiation and Type 2 re-irradiation in 309 (46.8 %) and 113 (17.1 %) cases, respectively. Median survival after the first course of radiotherapy was 3.6 (0.3-13.4) years. Response to radiotherapy was observed in 548 (83.0 %) cases and CTCAE toxicity grade ≥ 3 was observed in 21 (3.2 %) cases. An increasing number of RT courses (HR: 1.30, p=<0.0001), Type 1 re-irradiation (HR 3.50, p = 0.008) and KPS ≤ 80 % (HR: 2.02, p = 0.002) were associated with significantly worse treatment responses. Toxicity rates remained stable with increasing numbers of RT courses. Conclusion: Multiple courses of repeat radiotherapy maintain a favorable therapeutic ratio of high response combined with reasonable safety profile.

Indexed as

Local controlRadiation therapyRe-irradiationRepeat radiotherapyToxicity

Identifiers

PMID37867613
PMCPMC10589769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.